Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease

Author(s): Francesco Tovoli, Silvia Ferri, Fabio Piscaglia*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 32 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Non-alcoholic fatty liver disease (NAFLD) is a global epidemic involving 20-40% of the general population. NAFLD is rapidly becoming the leading cause of hepatocellular carcinoma (HCC) worldwide. Knowledge about NAFLD-HCC peculiar features is needed to understand this emerging disease better.

Objective: To review the current literature about the epidemiological, pathogenic and clinical features characterising the NAFLD and distinguishing it from HCC of other etiologies.

Methods: A systematic review of the literature (PubMed and Medline) using the following string ("Non-alcoholic Fatty Liver Disease"[Mesh] and "Carcinoma, Hepatocellular"[Mesh]). Particular relevance was given to papers published in the last five years as well as previously published manuscript very relevant to this topic according to the experience of the authors.

Results: A total of 244 original papers in humans in English literature were analysed. Inherent difficulties in the identification of high-risk subjects and the possibility of occurrence in non-cirrhotic livers are peculiar characteristics of NAFLD-HCC hampering surveillance programs. The consequently delayed diagnosis limits access to surgical procedures and impacts on survival. After correction for tumour burden, however, the survival is not different from that of viral HCC, suggesting that NAFLD-HCC is not intrinsically a more aggressive malignancy.

Conclusion: A great deal of effort is needed to improve the clinical outcome of NAFLD-HCC, especially in terms of prevention, surveillance protocols, and identification of drug modifying the natural history of the underlying liver disease. The outcome of these efforts will significantly impact global HCC-related costs and mortality.

Keywords: Hepatocellular carcinoma, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver steatosis, outcome, NAFLD-HCC.

[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[2]
McQuaid T, Savini C, Seyedkazemi S. Sofosbuvir, a significant paradigm change in HCV treatment. J Clin Transl Hepatol 2015; 3(1): 27-35.
[http://dx.doi.org/10.14218/JCTH.2014.00041] [PMID: 26357632]
[3]
Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17(11): 863-9.
[http://dx.doi.org/10.1016/j.annepidem.2007.05.013] [PMID: 17728149]
[4]
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142(6): 1264-73.e1.
[http://dx.doi.org/10.1053/j.gastro.2011.12.061] [PMID: 22537432]
[5]
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388-402.
[http://dx.doi.org/10.1016/j.jhep.2015.11.004] [PMID: 27062661]
[6]
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59(6): 2188-95.
[http://dx.doi.org/10.1002/hep.26986] [PMID: 24375711]
[7]
Wong VW. Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol 2013; 28(1): 18-23.
[http://dx.doi.org/10.1111/jgh.12011] [PMID: 23094755]
[8]
Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57(4): 1357-65.
[http://dx.doi.org/10.1002/hep.26156] [PMID: 23175136]
[9]
Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32(1): 3-13.
[http://dx.doi.org/10.1055/s-0032-1306421] [PMID: 22418883]
[10]
Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41(6): 1313-21.
[http://dx.doi.org/10.1002/hep.20701] [PMID: 15915461]
[11]
Bedossa P. FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60(2): 565-75.
[http://dx.doi.org/10.1002/hep.27173] [PMID: 24753132]
[12]
McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62(5): 1148-55.
[http://dx.doi.org/10.1016/j.jhep.2014.11.034] [PMID: 25477264]
[13]
Pais R, Charlotte F, Fedchuk L, et al. LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59(3): 550-6.
[http://dx.doi.org/10.1016/j.jhep.2013.04.027] [PMID: 23665288]
[14]
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274-85.
[http://dx.doi.org/10.1111/j.1365-2036.2011.04724.x] [PMID: 21623852]
[15]
Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018; 155(6): 1828-37.e2.
[http://dx.doi.org/10.1053/j.gastro.2018.08.024] [PMID: 30144434]
[16]
Stefano JT, de Oliveira CP, Corrêa-Giannella ML, et al. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression? Liver Int 2011; 31(3): 377-85.
[http://dx.doi.org/10.1111/j.1478-3231.2010.02370.x] [PMID: 21108736]
[17]
Tovoli F, Napoli L, Negrini G, et al. A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease. Int J Mol Sci 2017; 18(6): 18.
[http://dx.doi.org/10.3390/ijms18061134] [PMID: 28587063]
[18]
Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol 2012; 12: 20.
[http://dx.doi.org/10.1186/1471-230X-12-20] [PMID: 22380754]
[19]
Piccinin E, Villani G, Moschetta A. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. Nat Rev Gastroenterol Hepatol 2019; 16(3): 160-74.
[http://dx.doi.org/10.1038/s41575-018-0089-3] [PMID: 30518830]
[20]
Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014; 61(1): 75-81.
[http://dx.doi.org/10.1016/j.jhep.2014.02.030] [PMID: 24607626]
[21]
Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46(4): 352-6.
[http://dx.doi.org/10.1038/ng.2901] [PMID: 24531328]
[22]
Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46(4): 345-51.
[http://dx.doi.org/10.1038/ng.2926] [PMID: 24633158]
[23]
Zhou Y, Llauradó G, Orešič M, Hyötyläinen T, Orho-Melander M, Yki-Järvinen H. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. J Hepatol 2015; 62(3): 657-63.
[http://dx.doi.org/10.1016/j.jhep.2014.10.010] [PMID: 25457209]
[24]
Kutlu O, Kaleli HN, Ozer E. Molecular pathogenesis of nonalcoholic steatohepatitis- (NASH-) related hepatocellular carcinoma. Can J Gastroenterol Hepatol 2018; 2018 8543763
[http://dx.doi.org/10.1155/2018/8543763] [PMID: 30228976]
[25]
Brandi G, De Lorenzo S, Candela M, et al. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis 2017; 38(3): 231-40.
[http://dx.doi.org/10.1093/carcin/bgx007] [PMID: 28426878]
[26]
Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 2019; 69(1): 107-20.
[http://dx.doi.org/10.1002/hep.30036] [PMID: 29665135]
[27]
Singh V, Yeoh BS, Chassaing B, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic Liver. Cancer Cell 2018; 175(3): 679-94.e22.
[http://dx.doi.org/10.1016/j.cell.2018.09.004] [PMID: 30340040]
[28]
Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015; 13(3): 594-601.e1.
[http://dx.doi.org/10.1016/j.cgh.2014.08.013] [PMID: 25148760]
[29]
Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015; 62(6): 1723-30.
[http://dx.doi.org/10.1002/hep.28123] [PMID: 26274335]
[30]
El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126(2): 460-8.
[http://dx.doi.org/10.1053/j.gastro.2003.10.065] [PMID: 14762783]
[31]
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54(4): 533-9.
[http://dx.doi.org/10.1136/gut.2004.052167] [PMID: 15753540]
[32]
Bosetti C, Rosato V, Polesel J, et al. Diabetes mellitus and cancer risk in a network of case-control studies. Nutr Cancer 2012; 64(5): 643-51.
[http://dx.doi.org/10.1080/01635581.2012.676141] [PMID: 22519904]
[33]
Degasperi E, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2016; 1(2): 156-64.
[http://dx.doi.org/10.1016/S2468-1253(16)30018-8] [PMID: 28404072]
[34]
Turati F, Talamini R, Pelucchi C, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013; 108(1): 222-8.
[http://dx.doi.org/10.1038/bjc.2012.492] [PMID: 23169288]
[35]
Lee YC, Cohet C, Yang YC, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 2009; 38(6): 1497-511.
[http://dx.doi.org/10.1093/ije/dyp280] [PMID: 19720726]
[36]
Abdel-Rahman O, Helbling D, Schöb O, et al. Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies. J Evid Based Med 2017; 10(4): 245-54.
[http://dx.doi.org/10.1111/jebm.12270] [PMID: 28891275]
[37]
Heath RD, Brahmbhatt M, Tahan AC, Ibdah JA, Tahan V. Coffee: The magical bean for liver diseases. World J Hepatol 2017; 9(15): 689-96.
[http://dx.doi.org/10.4254/wjh.v9.i15.689] [PMID: 28596816]
[38]
Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60(1): 110-7.
[http://dx.doi.org/10.1016/j.jhep.2013.08.011] [PMID: 23978719]
[39]
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63(3): 827-38.
[http://dx.doi.org/10.1002/hep.28368] [PMID: 26599351]
[40]
Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61(5): 1547-54.
[http://dx.doi.org/10.1002/hep.27368] [PMID: 25125077]
[41]
Cucchetti A, Cescon M, Erroi V, Pinna AD. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol 2013; 27(6): 961-72.
[http://dx.doi.org/10.1016/j.bpg.2013.08.021] [PMID: 24182614]
[42]
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018; 24(30): 3361-73.
[http://dx.doi.org/10.3748/wjg.v24.i30.3361] [PMID: 30122876]
[43]
Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51(3): 828-35.
[http://dx.doi.org/10.1002/hep.23425] [PMID: 20063276]
[44]
Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51(2): 454-62.
[http://dx.doi.org/10.1002/hep.23312] [PMID: 20101745]
[45]
Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107(12): 1862-71.
[http://dx.doi.org/10.1038/ajg.2012.331] [PMID: 23032979]
[46]
Boursier J, Francque S. Noninvasive tests of liver fibrosis and their combination in NAFLD: From selected patients to real-life populations. Hepatology 2019. Epub ahead of print
[http://dx.doi.org/10.1002/hep.30886] [PMID: 31381156]
[47]
Schiavone C, Piscaglia F, Iannetti G, Cantisani V. What ultrasound operators must be well aware of in a world with raising burden of non alcoholic fatty liver disease? Ultraschall Med 2019; 40(1): 7-10.
[http://dx.doi.org/10.1055/a-0808-8062] [PMID: 30769360]
[48]
European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63(1): 237-64.
[http://dx.doi.org/10.1016/j.jhep.2015.04.006] [PMID: 25911335]
[49]
Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47(2): 455-60.
[http://dx.doi.org/10.1002/hep.21984] [PMID: 18038452]
[50]
Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: Baseline data from the STELLAR trials. Hepatology 2019; 70(5): 1521-30. Epub ahead of print
[http://dx.doi.org/10.1002/hep.30842] [PMID: 31271665]
[51]
Tavakoli H, Robinson A, Liu B, et al. Cirrhosis patients with nonalcoholic steatohepatitis are significantly less likely to receive surveillance for hepatocellular carcinoma. Dig Dis Sci 2017; 62(8): 2174-81.
[http://dx.doi.org/10.1007/s10620-017-4595-x] [PMID: 28474143]
[52]
Than NN, Ghazanfar A, Hodson J, et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017; 110(2): 73-81.
[PMID: 27634970]
[53]
Sadler EM, Mehta N, Bhat M, et al. Liver transplantation for NASH-related hepatocellular carcinoma versus non-nash etiologies of hepatocellular carcinoma. Transplantation 2018; 102(4): 640-7.
[http://dx.doi.org/10.1097/TP.0000000000002043] [PMID: 29319620]
[54]
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017; 46(11-12): 1061-9.
[http://dx.doi.org/10.1111/apt.14342] [PMID: 28960360]
[55]
Viganò L, Conci S, Cescon M, et al. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC. J Hepatol 2015; 63(1): 93-101.
[http://dx.doi.org/10.1016/j.jhep.2015.01.024] [PMID: 25646890]
[56]
Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012; 55(6): 1809-19.
[http://dx.doi.org/10.1002/hep.25536] [PMID: 22183968]
[57]
Gilead announces topline data from phase-3 stellar3 study of selonsertib in bridging fibrosis f3 due to nonalcoholic steatohepatitisnash. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2019/4/gilead-announces-topline-data-from-phase-3-stellar3-study-of-selonsertib-in-bridging-fibrosis-f3-due-to-nonalcoholic-steatohepatitis-nash
[58]
Gilead announces topline data from phase-3 stellar 4 study of selonsertib in compensated cirrhosis f4 due to nonalcoholic steatohepatitis Nash. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2019/2/gilead-announces-topline-data-from-phase-3-stellar4-study-of-selonsertib-in-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash
[59]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 32
Year: 2020
Published on: 23 September, 2020
Page: [3909 - 3914]
Pages: 6
DOI: 10.2174/1381612826666200429093648
Price: $65

Article Metrics

PDF: 18
HTML: 1